R&D | October 08, 2025
Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction
New study presents a human-relevant stress model for assessing potential therapeutics
New study presents a human-relevant stress model for assessing potential therapeutics
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Subscribe To Our Newsletter & Stay Updated
